<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144468">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01723085</url>
  </required_header>
  <id_info>
    <org_study_id>AMH</org_study_id>
    <nct_id>NCT01723085</nct_id>
  </id_info>
  <brief_title>Anti-Mullerian Hormone Levels Before and After an Open Myomectomy</brief_title>
  <official_title>Anti-Mullerian Hormone Levels Variations Following an Open Myomectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OVO R &amp; D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OVO R &amp; D</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anti-Mullerian hormone (AMH) is a marker for ovarian reserve.  It is well known that ovarian
      surgery for endometriosis lowers Anti-Mullerian hormone, but little is known for other
      surgeries.  We seek to investigate the hormone variations before and after an open
      myomectomy.

      Hypothesis: Anti-Mullerian hormone levels drop following surgery but return to normal levels
      in a few months
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Anti-Mullerian Hormone levels variation</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Anti-Mullerian Hormone levels before and 6 months after surgery</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Anti-Mullerian Hormone</condition>
  <arm_group>
    <arm_group_label>Open myomectomy</arm_group_label>
    <description>All patients belong to the same group Description includes the surgical technique</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples collected to measure Anti-Mullerian hormone levels
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women 18 to 42 tears old Indication for myomectomy by laparotomy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 42 years old

          -  Requiring open myomectomy for any indication

        Exclusion Criteria:

          -  Incapable of informed consent

          -  Use of hormonal contraception or Gonadotropin-releasing hormone agonists in the past
             3 months

          -  Woman over 42 years old

          -  Post-menopause women

          -  Positive B-human chorionic gonadotropin the day of surgery

          -  Ovarian surgery (at the same time)

          -  Pre-operative AMH below 0.3 ng/mL
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Himaya, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier de l'Université de Montréal</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric Himaya, MD</last_name>
    <phone>(514) 890-8000</phone>
    <email>ehimaya@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hopital Saint-Luc</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3J4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Himaya, MD</last_name>
      <phone>(514) 890-8000</phone>
      <email>ehimaya@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Eric Himaya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 21, 2013</lastchanged_date>
  <firstreceived_date>November 5, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti-Mullerian hormone</keyword>
  <keyword>Myomectomy</keyword>
  <keyword>Laparotomy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
